ライフサイエンスコーパス: per minute

1 and tachycardia (mean heart rate, >93 beats per minute).

2 d rest (4-6 minutes IV adenosine, 140 mug/kg per minute).

3 ion with traffic density (number of vehicles per minute).

4 in were significantly different (0.3% change per minute).

5 inute and a 1.0-second delay at >/=200 beats per minute).

6 mug/kg per minute), and high-dose (>5 mug/kg per minute).

7 6) compared with controls (16.7+/-1.37 mL/kg per minute).

8 age oxygen consumption was 1.1 +/- 0.2 mL/kg per minute.

9 logical pacemaker rates were 45 and 75 beats per minute.

10 ated creatinine clearance of more than 60 mL per minute.

11 onditions at stimulation rates of 60 and 180 per minute.

12 ute to a minimum of 8500 +/- 380 revolutions per minute.

13 were superfused and stimulated at 100 beats per minute.

14 8 (95% confidence interval: 0.04, 1.92) beat per minute.

15 demonstrated normal sinus rhythm at 73 beats per minute.

16 chieve a target heart rate of 55 to 60 beats per minute.

17 tests when sinus rate exceeded 99+/-17 beats per minute.

18 tachycardia with a median rate of 230 beats per minute.

19 rable neurological outcome decreased by 1.2% per minute.

20 reading process accounts for three particles per minute.

21 and a measurement rate of approximately once per minute.

22 alysis with throughput of about four samples per minute.

23 on to maintain heart rate less than 95 beats per minute.

24 enge at doses of 0.05, 0.10, and 0.20 mug/kg per minute.

25 were still in AF with a heart rate >80 beats per minute.

26 ents in the open-label stage was 0.75 mug/kg per minute.

27 apshot, one-gigapixel images at three frames per minute.

28 ompression rate of at least 100 compressions per minute.

29 t decrease in heart rate from 74 to 64 beats per minute.

30 tching beats from 35+/-4.3 to 65+/-4.0 beats per minute.

31 , and vascular resistance 153 +/- 16 mm Hg/L per minute.

32 rminus (>2 megabases) at rates >50 kilobases per minute.

33 d the mean single-nephron GFR was 80+/-40 nl per minute.

34 mm Hg or a heart rate greater than 120 beats per minute.

35 c chronotropic response upon tilt > 10 beats per minute.

36 ated creatinine clearance of more than 60 mL per minute.

37 placement, at the equivalent of two letters per minute.

38 ughput of over 1.95 x 10(6) reads classified per minute.

39 men with resting heart rates below 62 beats per minute.

40 /- 3.2 with median 0 (range, -8 to 17) beats per minute.

41 rmational change at rates of up to one cycle per minute.

42 1.72, 1.19-2.49); and heart rate 60-90 beats per minute (1.21, 0.89-1.63) and >/=90 beats per minute

43 +/- standard deviation PF was 18.9 mL/100 mL per minute +/- 11.0 and mean MTT was 213.3 seconds +/- 5

44 The mean heart rate was 57.1 beats per minute +/- 11.2 (range, 34-96 beats per minute), whi

45 ental doses (50 mug/kg per minute, 80 mug/kg per minute, 110 mug/kg per minute, and 140 mug/kg per mi

46 dard deviation) in the AF group and 63 beats per minute +/- 14 in the SR group (P < .01).

47 per minute (1.21, 0.89-1.63) and >/=90 beats per minute (2.35, 1.03-5.33).

48 ially tested in a euthanized pig at 60 beats per minute, 2 V amplitude, and 1 ms pulse width, restori

49 less during play with electronic toys (mean per minute, 2.9; 95% CI, 2.16-3.69) than during play wit

50 Mean heart rate during scanning was 83 beats per minute +/- 21 (standard deviation) in the AF group a

51 2.16-3.69) than during play with books (mean per minute, 3.91; 95% CI, 3.09-4.68).

52 ower during play with traditional toys (mean per minute, 4.09; 95% CI, 3.26-4.99) than during play wi

53 ords during play with traditional toys (mean per minute, 55.56; 95% CI, 46.49-64.17) than during play

54 3.26-4.99) than during play with books (mean per minute, 6.96; 95% CI, 6.07-7.97).

55 tion of N2 into NH3 The turnover rate was 75 per minute, 63% of the ATP-coupled reaction rate for the

56 .49-64.17) than during play with books (mean per minute, 66.89; 95% CI, 59.93-74.19) and use of conte

57 eline and under incremental doses (50 mug/kg per minute, 80 mug/kg per minute, 110 mug/kg per minute,

58 ute, respectively; mean difference, 8.3 mL/g per minute [95% CI of mean difference, 1.87-14.70]; P =

59 uptake (weighted mean difference, 1.8 mL/kg per minute; 95% confidence interval, 1.4-2.3), pulmonary

60 ed with higher adenoma detection rates (3.6% per minute; 95% confidence interval: 2.4% to 4.8%; P < .

61 (with a 60-second delay at 170 to 199 beats per minute, a 12-second delay at 200 to 249 beats per mi

62 degrees C, a respiratory rate of 48 breaths per minute, a heart rate of 158 beats per minute, decrea

63 ted heart rates, rising as much as 123 beats per minute above the pre-flight baseline.

64 nute) and PDE3-specific (48.2+/-15.9 pmol/mg per minute) activities in comparison with those of nonfa

65 110 mug/kg per minute but not at 140 mug/kg per minute adenosine infusion rate, with mean difference

66 sociated with NSVT runs at a rate >200 beats per minute (adjusted hazard ratio, 15.63; 95% confidence

67 max rose from 40.3+/-1.6 to 48.7+/-2.5 mL/kg per minute after 1 year (P<0.00001), associated with an

68 (with a 2.5-second delay at 170 to 199 beats per minute and a 1.0-second delay at >/=200 beats per mi

69 terval prolonged by >/= 30 ms at 0.10 mug/kg per minute and borderline if QT prolongation was 1 to 29

70 stimated initial rate of over 1000 turnovers per minute and can be used under aerobic conditions.

71 vein ablation, the PN was paced at 60 beats per minute and diaphragmatic compound motor action poten

72 up-regulation (stroke frequency >25 strokes per minute and energetic costs three to six times the re

73 Such transients average approximately two per minute and last approximately 30 s.

74 ing sinus rhythms with heart rate <100 beats per minute and QRS duration <120 ms constituted our data

75 statement (assuming sinus rhythm <100 beats per minute and QRS duration <120 ms), physicians should

76 g was performed by pacing the right PN at 60 per minute and recording diaphragmatic compound motor ac

77 heart rate greater than or equal to 95 beats per minute and requiring norepinephrine to maintain mean

78 measured during adenosine stress (140 mug/kg per minute) and at rest by model-independent deconvoluti

79 erformed during adenosine stress (140 mug/kg per minute) and at rest on a Siemens 1.5-T Avanto scanne

80 product (in milliliters per 100 milliliters per minute) and blood volume (in milliliters per 100 mil

81 93 (HEK) (Km 3.8 microM and Vmax 307 pmol/mg per minute) and HeLa (Km 0.32 microM and Vmax 42 pmol/mg

82 IV, sinus rhythm, and heart rate >/=70 beats per minute) and non-SHIFT type.

83 area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of bo

84 gher total PDE-specific (74.6+/-13.8 pmol/mg per minute) and PDE3-specific (48.2+/-15.9 pmol/mg per m

85 arts consumed oxygen (0.09 +/- 0.01 mL/100 g per minute) and showed decreasing lactate production in

86 tressful part of the film clip (by 2 breaths per minute) and was well matched in the respective contr

87 d into 3 groups: none, low-dose (</=5 mug/kg per minute), and high-dose (>5 mug/kg per minute).

88 per minute, 80 mug/kg per minute, 110 mug/kg per minute, and 140 mug/kg per minute) of adenosine infu

89 inute, a 12-second delay at 200 to 249 beats per minute, and a 2.5-second delay at >/=250 beats per m

90 ion of CPR time with a CC rate of 100 to 120 per minute, and CC fraction (percentage CPR time) during

91 e of 73 years, creatinine clearance of 62 ml per minute, and CIRS score of 8 at baseline.

92 of CPR, survival decreased linearly by 2.1% per minute, and rates of favorable neurological outcome

93 ons: ventricular pacing at 200 and 300 beats per minute, and ventricular fibrillation.

94 ement of peak oxygen consumption (Vo2 [mL/kg per minute]) and ventilatory efficiency (the VE/Vco2 slo

95 Acute infusion of 30, 60, or 80 ng/kg per minute Ang II enhanced the endocytosis of albumin by

96 , compared with none at baseline or 10 ng/kg per minute Ang II.

97 /s, which corresponds to 0.045 million cells per minute at the designed geometry, which is over 2 ord

98 nt platform, four titrations can be obtained per minute (based on approximately 100 data points each)

99 heart rates (80.8 versus 61.7 and 68.0 beats per minute; both P<0.05).

100 percentile) baseline heart rate was 63 beats per minute (bpm) (57-71 bpm).

101 .6 mmHg), heart rate [HR; -4.0 +/- 1.7 beats per minute (bpm)], triglycerides (-72 +/- 38.2 mg/dl), i

102 nant (P) mice have faster HR (531+/-14 beats per minute [bpm]) compared with nonpregnant (NP) mice (4

103 40-358; P < .01), resting HR (mean, 84 beats per minute [bpm]; 95% CI, 82-86 to 74 bpm; 95% CI, 72-76

104 lor than prasugrel at 50, 80, and 110 mug/kg per minute but not at 140 mug/kg per minute adenosine in

105 Spontaneous events were infrequent (0.3 per minute), but the rate and amplitude were increased a

106 rdia index was only 15% for FHR </=110 beats per minute, but 66% for FHR </=3rd percentile for GA.

107 and HeLa (Km 0.32 microM and Vmax 42 pmol/mg per minute) cells.

108 odium depletion or angiotensin II (0.5 ng/kg per minute) coinfusion (P>0.05 for all).

109 ast 15-minute interval (2.66 +/- 0.55 cycles per minute) compared to the baseline recording (2.81 +/-

110 Chest compression rate was 111+/-19 per minute, compression fraction was 0.70+/-0.17, and co

111 ssion rates closer to 85 to 100 compressions per minute (cpm) than nonsurvivors (absolute mean differ

112 and mean level of physical activity (counts per minute [CPM], steps, time spent in light, moderate o

113 ean total volumes of PA (accelerometer count per minute, cpm) and moderate-vigorous intensity PA (MVP

114 reaths per minute, a heart rate of 158 beats per minute, decreased breath sounds on the left side, an

115 rological outcome (multivariable-adjusted RR per minute delay, 0.95 [95% CI, 0.91-0.99]).

116 ysis (multivariable-adjusted risk ratio [RR] per minute delay, 0.95 [95% CI, 0.93-0.98]).

117 vival at 24 hours (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.95-0.99]), and decreas

118 ased risk of ROSC (multivariable-adjusted RR per minute delay, 0.97 [95% CI, 0.96-0.99]), decreased r

119 illations in zebrafish exploration, with the per-minute distribution of their horizontal activity dem

120 s per minute; single mutation, 134+/-8 beats per minute; double mutations, 111+/-6 beats per minute;

121 oration assay, which provides disintegration-per-minute (DPM) values that are negatively associated w

122 ion periods and total compressions delivered per minute during each 2 minutes of cardiopulmonary resu

123 semantic categories (content-specific words) per minute during play sessions.

124 o the constrictions of several hundred cells per minute during their passage through the device.

125 ntravenous infusion of adenosine (140 mug/kg per minute, FFRiv).

126 dose of 0.2 mug per kilogram of body weight per minute for 1 hour, followed by a dose of 0.1 mug per

127 s atrial and ventricular pacing at 220 beats per minute for 14 days.

128 , followed by a dose of 0.1 mug per kilogram per minute for 23 hours) or placebo, with the infusion s

129 semide plus TRV120027 (0.3 and 1.5 microg/kg per minute for 45 minutes each); 2 clearances were done

130 receive either supplemental oxygen (6 liters per minute for 6 to 12 hours, delivered through an open

131 f high-rate ventricular pacing (at 220 beats per minute for the first 4 weeks to develop HF and anoth

132 -controlled diet, we infused Ang II (3 ng/kg per minute) for 1 hour in patients with POTS (n=15) and

133 0.05 to 0.2 mug per kilogram of body weight per minute) for 24 hours or placebo in addition to stand

134 10(5) to 10(7) per flush from the toilets or per minute from the lab-scale models, and the total volu

135 (>/=10 cm H2O), and corrected expired volume per minute (>/=10 L/min).

136 ion) with resting heart rates above 82 beats per minute had a 69% (95% CI, 46%-94%) increased risk fo

137 scan cycle speed of approximately 45 full MS per minute, improving the definition of extracted LC-MS

138 talyzed the hydrolysis of 1.0 mumol of TAPTA per minute in a pH 7.40 phosphate buffer saline solution

139 proximately 10(-9) to 10(-7) mL per flush or per minute in all cases.

140 ating>/=150 minutes per week at >/=100 steps per minute in bouts lasting >/=10 minutes.

141 essions (CCs) and 30 manual inflations (3:1) per minute in newborns.

142 of reducing heart rate to less than 95 beats per minute in patients with septic shock using the beta-

143 The percentage change per minute in radioactivity concentration was calculated

144 rt rate of the patients was 60.7+/-9.0 beats per minute in the ivabradine group versus 70.6+/-10.1 be

145 e transients, with peaks averaging up to six per minute in the peripheral domain.

146 he ivabradine group versus 70.6+/-10.1 beats per minute in the placebo group.

147 /100 mL per minute versus 132+/-40 mL/100 mL per minute in those with preserved cardiac index (>/=2.5

148 as within the normal range (2.3 - 3.5 cycles per minute) in all animals in all regimens.

149 ffect of 4-week infusion of AngII (400 ng/kg per minute) in APA-KO and wild-type mice.

150 sponses to step changes (200-400 revolutions per minute) in continuous-flow left ventricular assist d

151 namic response during exercise (>3.0 mm Hg/L per minute increase), with 91% sensitivity and 82% speci

152 ion (milliliters per kilogram of body weight per minute) increased more in the combination and aerobi

153 ortical acetylcholinesterase hydrolysis rate per minute (k3), respectively.

154 as comparable when expressed in kilocalories per minute (L: 2.6 +/- 0.2 kcal/min; H: 2.9 +/- 0.3 kcal

155 have a net negative change in neurite length per minute, leading to a reduction of overall neurite le

156 Faster rate (>200 beats per minutes), longer (>7 beats), and repetitive runs of

157 s /s), exercise capacity (-2.0 +/- 2.1 ml/kg per minute), low-back and hamstring flexibility (-4.7 +/

158 ificant increases in HR (+69.3 +/- 8.5 beats per minute); MAP (+22.9 +/- 1.6 mm Hg); IOP (+7.1 +/- 1.

159 ll patients, median compression rate was 106 per minute, median compression fraction 0.65, and median

160 c from total binding measurements (in decays per minute/mm(2), DPM mm(2)) and was compared with cardi

161 A cutting throughput up to 64 cells per minute-more than 200 times faster than current metho

162 Men with HR100W <100 beats per minute (n=260) were characterized by high physical f

163 e-aorta with norepinephrine at 0.1 microg/kg per minute (n=4).

164 ular tachypacing (2-6 weeks at 200-240 beats per minute; n=17).

165 ebulizer temperature and 1.1 standard litres per minute nitrogen flow rate.

166 cebo, neither low-dose dopamine (2 microg/kg per minute) nor low-dose nesiritide (0.005 mug/kg per mi

167 % of LQTS FHR recordings either </=110 beats per minute (obstetric standard) or </=3(rd) percentile f

168 Per minute of exposure, the 0.2 h duration was over 5 ti

169 ability of swine-to-human H3N2v transmission per minute of swine contact.

170 inute, 110 mug/kg per minute, and 140 mug/kg per minute) of adenosine infusion.

171 ons containing a mixture of droplets at >150 per minute, opening up new routes to high throughput scr

172 nts with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive

173 carboplatin area under the curve >/= 4 mg/mL per minute or high-dose chemotherapy, and for pediatric

174 therapies for tachyarrhythmias of 200 beats per minute or higher or with a prolonged delay in therap

175 th a prolonged delay in therapy at 170 beats per minute or higher, as compared with conventional prog

176 a dose of 15 ng per kilogram of body weight per minute or matching placebo for 48 hours, in addition

177 l heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activ

178 d an estimated creatinine clearance of 60 ml per minute or more, in a 2:1 ratio to receive tolvaptan,

179 ar dysfunction, and a heart rate of 70 beats per minute or more.

180 f norepinephrine per kilogram of body weight per minute or the equivalent dose of another vasopressor

181 CI, 1.1-2.1), respiratory rate >/=30 breaths per minute (OR, 1.6; 95% CI, 1.1-2.3), blood pH <7.35 (O

182 n of therapy at a heart rate of >/=200 beats per minute) or delayed therapy (with a 60-second delay a

183 ther high-flow nasal cannulae (5 to 6 liters per minute) or nasal CPAP (7 cm of water) after extubati

184 0.025 to 0.2 mug per kilogram of body weight per minute) or placebo, for up to 48 hours or until disc

185 s of micromoles hydrogen peroxide decomposed per minute over a period of 348 s, was found to vary wit

186 abilitation program were 48.31+/-22.06 words per minute (P<0.001), 35.46+/-15.68 minutes (P<0.001), a

187 ) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009 for within-group changes), whereas n

188 er minute vs 7 hours, 0.34 +/- 0.05 mm Hg/mL per minute, P = 0.005).

189 eta-blocker exposure each predicted -7 beats per minute, P<0.0001.

190 perative JET from 148+/-31 to 106+/-32 beats per minute, P<0.001, and restored sinus rhythm in 7/7 do

191 response rate from 166+/-58 to 63+/-29 beats per minute, P<0.001.

192 , P=0.08; 77.4+/-7.3 versus 78.8+/-6.0 beats per minute, P=0.50, respectively).

193 esia: 3.25 +/- 0.34 and 3.29 +/- 0.38 cycles per minute; p < 0.001, p = 0.003, p < 0.001, p < 0.001).

194 per minute; double mutations, 111+/-6 beats per minute; P<0.0001), and lower in symptomatic versus a

195 tion carriers (122+/-10 versus 137+/-9 beats per minute; P<0.0001).

196 +/-25 beats per minute versus 136+/-24 beats per minute; P<0.001) and to reduced peak stroke volume i

197 /-7.7 mL/kg per minute; UC, 23.4+/-6.0 mL/kg per minute; P<0.001).

198 sumption, 44.6+/-5.2 versus 46.3+/-5.4 mL/kg per minute; P<0.001).

199 rvedilol (308 +/- 25 versus 351 +/- 31 beats per minute; P<0.001).

200 low speed: 41 +/- 15 versus 33 +/- 16 bursts per minute; P<0.01) despite a reduction in mean arterial

201 +/-44 beats per minute versus 229+/-31 beats per minute; P=0.001), and longer ventriculo-atrial times

202 /-7.0 mL/kg per minute; UC, 23.9+/-6.6 mL/kg per minute; P=0.002) at 8 weeks, which persisted during

203 ly lower in the PAH group (12.6+/-1.31 mL/kg per minute; P=0.01) and trended toward lower in the tetr

204 ygen consumption (22+/-6 versus 18+/-6 mL/kg per minute; P=0.014) and Minnesota living with HF questi

205 tetralogy of Fallot group (13.5+/-1.29 mL/kg per minute; P=0.06) compared with controls (16.7+/-1.37

206 e tolvaptan group, as compared with -3.61 ml per minute per 1.73 m(2) (95% CI, -4.08 to -3.14) in the

207 m baseline in the estimated GFR was -2.34 ml per minute per 1.73 m(2) (95% confidence interval [CI],

208 1.73 m(2) or greater than or equal to 60 ml per minute per 1.73 m(2) (net reclassification index, 19

209 had a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) (P=0.75).

210 ile of suPAR levels as compared with -4.2 ml per minute per 1.73 m(2) among participants in the highe

211 p; the annual change in the eGFR was -0.9 ml per minute per 1.73 m(2) among participants in the lowes

212 f those with an estimated GFR of 45 to 59 ml per minute per 1.73 m(2) as having a GFR of 60 ml or hig

213 and a decrease in the eGFR of at least 15 ml per minute per 1.73 m(2) at the end of the trial.

214 in the estimated GFR (a decline of >/= 30 ml per minute per 1.73 m(2) if the initial estimated GFR wa

215 lar filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then r

216 d glomerular filtration rate [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from basel

217 Mean measured GFRs were 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the dev

218 of age with an estimated GFR of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 6

219 glomerular filtration rate of at least 30 ml per minute per 1.73 m(2) of body-surface area to receive

220 the prevalence of an eGFR of less than 60 ml per minute per 1.73 m(2) of body-surface area was higher

221 omerular filtration rate [GFR], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardox

222 ated glomerular filtration rate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either

223 lomerular filtration rate [GFR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receiv

224 pment of chronic kidney disease (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were anal

225 ed GFR were -0.30+/-0.66 and -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectiv

226 ) if the initial estimated GFR was >/= 60 ml per minute per 1.73 m(2) or a decline of >/= 50% if the

227 on of measured GFR as either less than 60 ml per minute per 1.73 m(2) or greater than or equal to 60

228 of age with an estimated GFR of 25 to 44 ml per minute per 1.73 m(2) were randomly assigned in a 1:1

229 between measured and estimated GFR of 3.9 ml per minute per 1.73 m(2) with the combined equation, as

230 ed equation, as compared with 3.7 and 3.4 ml per minute per 1.73 m(2) with the creatinine equation an

231 1 participants with a normal eGFR (>/= 90 ml per minute per 1.73 m(2)) at baseline had the largest su

232 ated confounders, lower eGFR (in milliliters per minute per 1.73 m(2)) was associated with an increas

233 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD

234 of the difference, 13.4 vs. 15.4 and 16.4 ml per minute per 1.73 m(2), respectively [P=0.001 and P<0.

235 ated GFR based on creatinine was 45 to 74 ml per minute per 1.73 m(2), the combined equation improved

236 pants with a baseline eGFR of at least 60 ml per minute per 1.73 m(2), the risk of progression to chr

237 1.73 m(2) as having a GFR of 60 ml or higher per minute per 1.73 m(2).

238 4) in the placebo group (difference, 1.27 ml per minute per 1.73 m(2); 95% CI, 0.86 to 1.68; P<0.001)

239 fference in cerebral blood flow [milliliters per minute per 100 ml] per doubling of the albumin-to-cr

240 y of variance in fetal heart rate (-10 beats per minute per added mutation; P<1.0x10(-23)).

241 in live animals can exceed 1 billion events per minute per gram of colonic contents, and multiphylum

242 The mean 11C HED RI was 0.086 mL of blood per minute per milliliter tissue+/-0.015 for control sub

243 5 for control subjects and 0.043 mL of blood per minute per milliliter tissue+/-0.016 for patients wi

244 AgCl electrodes was shown to pump microliter per minute-range flow through a 0.5-mm-diameter capillar

245 ontrols (59.5+/-14.4 and 35.5+/-12.8 pmol/mg per minute, respectively).

246 hing beats were 53+/-6.9 and 69+/-10.4 beats per minute, respectively, at 4 weeks.

247 deliver >60, >70, and >80 chest compressions per minute, respectively.

248 se vs fructose ingestion (-5.45 vs 2.84 mL/g per minute, respectively; mean difference, 8.3 mL/g per

249 Slow cooling (a few degrees Celsius per minute) resulted in much higher M. tuberculosis comp

250 icrochannel, metering chambers and revulsion per minute (RPM) control.

251 hour (kg/h) (0.6 to 600 standard cubic feet per minute (scfm)).

252 Slower (</=200 beats per minute), shorter (</=7), or a single run of NSVT wer

253 - 9.3 mL/kg per minute vs 44.1 +/- 8.8 mL/kg per minute), shorter exercise duration (9.3 +/- 2.8 minu

254 r added mutation (no mutation, 143+/-5 beats per minute; single mutation, 134+/-8 beats per minute; d

255 treme bradycardia with heart rate </=4 beats per minute) superimposed on exercise up-regulation (stro

256 KD; estimated creatinine clearance, >/=60 ml per minute), the vasopressin V2-receptor antagonist tolv

257 The mean GFR was 115+/-24 ml per minute, the mean number of nephrons was 860,000+/-37

258 For each increment of 10 beats per minute, the multivariable adjusted hazard ratios in

259 At higher flow rates of up to 3 mL H(2) per minute, the spectral interferences were reduced lead

260 ment in peak Vo2 from 14.5 (10.5-16.6) mL/kg per minute to 16.1 (13.2-18.6) mL/kg per minute (P=0.009

261 from a maximum of 10,480 +/- 315 revolutions per minute to a minimum of 8500 +/- 380 revolutions per

262 ously sampling micro-liter volumes of sample per minute to detect dynamic changes in target analyte c

263 develop HF and another 4 weeks at 180 beats per minute to maintain HF).

264 ular pump, contracting, on average, 80 times per minute to propel 8000 liters of blood through body t

265 stimated creatinine clearance of 30 to 69 ml per minute to receive chlorambucil, obinutuzumab plus ch

266 l pacing from cycle length 500 ms (120 beats per minute) to AF onset.

267 e exercise at 24 weeks (EX, 26.9+/-7.7 mL/kg per minute; UC, 23.4+/-6.0 mL/kg per minute; P<0.001).

268 eak oxygen consumption (EX, 26.7+/-7.0 mL/kg per minute; UC, 23.9+/-6.6 mL/kg per minute; P=0.002) at

269 s at ventricular pacing of 200 and 300 beats per minute, under ventricular fibrillation, the right at

270 dex (<2.5 L/min per m(2)): 94+/-30 mL/100 mL per minute versus 132+/-40 mL/100 mL per minute in those

271 pic response (peak heart rate 111+/-25 beats per minute versus 136+/-24 beats per minute; P<0.001) an

272 ic reciprocating tachycardia (176+/-44 beats per minute versus 229+/-31 beats per minute; P=0.001), a

273 h FFR using intravenous adenosine 140 mcg/kg per minute via a central femoral vein.

274 Vector magnitude counts per minute (VM CPM) and time per day spent in different

275 consumption (VO2max/kg) (37.5 +/- 9.3 mL/kg per minute vs 44.1 +/- 8.8 mL/kg per minute), shorter ex

276 course of perfusion (0 hour, 1.6 +/- 0.51 mm per minute vs 7 hours, 0.34 +/- 0.05 mm Hg/mL per minute

277 icted resting heart rate increase of 5 beats per minute was associated with a 20% increase in mortali

278 higher accelerometer-assessed average counts per minute was associated with lower all-cause mortality

279 ardia/ventricular fibrillation >/= 240 beats per minute was equivalent to the control survival rate.

280 claims, indicating that an increase in RVUs per minute was not concentrated in a small number of hig

281 aused by ventricular tachyarrhythmias >/=240 per minute was observed in 7 and 10 patients, respective

282 s, half maximal relaxation time (RT50) at 60 per minute was prolonged by 13% in HHD and by 18% in HHD

283 n during which </=2 L of supplemental oxygen per minute was received.

284 nute, and a 2.5-second delay at >/=250 beats per minute) was associated with a decrease in the number

285 Heart rates targeted between 80 and 94 beats per minute were achieved in all patients.

286 depth, compression rates between 100 and 120 per minute were associated with greatest survival to hos

287 ) compared with men with HR100W >/=100 beats per minute when adjusted for age, systolic blood pressur

288 high cell processing speed (20 million cells per minute) which remarkably outperforms previous device

289 eats per minute +/- 11.2 (range, 34-96 beats per minute), which enabled single-heartbeat scans in 100

290 ric rate threshold between 185 and 200 beats per minute, which exceeds the rate tested in clinical tr

291 termined a turnover number of eight peptides per minute, which is two orders of magnitude higher than

292 reased heart rate by approximately 145 beats per minute, which was not seen in KCa3.1(-/-) mice.

293 esolution at 40 cm), normalized by 200 words per minute, which was the mean value for a group of 365

294 mpared with intravenous infusion (140 mug/kg per minute), while requiring less time and offering supe

295 roximately 60 nt incorporated per telomerase per minute, with Km(dGTP) approximately 17 muM, indicati

296 inute) nor low-dose nesiritide (0.005 mug/kg per minute without bolus) enhanced decongestion or prese

297 5% coefficients of repeatability of 57 words per minute (wpm) and 2.76 wpm/minute.

298 cipants, compared to controls, read 46 words per minute (wpm) slower on MNRead (95% confidence interv

299 The number of correctly read words per minute (wpm) was reported.

300 pared with FBP75 (eg, 2.25-mm stent, 0 beats per minute; xy sharpness, 278.2 vs 252.3; signal-to-nois